CorMedix (CRMD) announced the appointment of Mr. Mike Seckler to the role of EVP & Chief Commercial Officer. Mr. Seckler joins CorMedix with a wealth of experience across multiple therapeutic areas including hematology and oncology, and most recently served as CEO of Evome Medical Technologies.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix sees Q4 revenue $127M, consensus $127.52M
- DefenCath’s Strong Clinical and Economic Profile Underpins Buy Rating Despite Anticipated 2026 Pricing Headwinds
- CorMedix announces interim results for DefenCath
- Cormedix’s Promising Outlook: Strong Financial Performance, Strategic Acquisition, and Growth Catalysts Justify Buy Rating
- CorMedix price target raised to $18 from $17 at H.C. Wainwright